Prolevare contains oclacitinib maleate, a JAK inhibitor. It is indicated for the treatment of pruritus associated with allergic dermatitis in dogs and the treatment of clinical manifestations of atopic dermatitis in dogs.
The product has only just received a positive opinion for initial marketing with the EMA on the 21st February 2023 so it will be a while before it is released onto the veterinary market. We will provide more information on the product when it becomes available.
If you have any specific questions regarding Prolevare please contact our customer services on [email protected].
Written by: Dr. Nick Garside BVetMed MRCVS
